MedPAC Analysis Of 'Low-Value' Medicare Treatments Spotlights Acthar
Executive Summary
The Medicare Payment Advisory Commission’s annual 2018 report to Congress features the flip side of the recent value-based rhetoric – highlighting “low-value” Medicare purchases. The drug chosen to make that argument is Mallinckrodt’s HP Acthar Gel.
You may also be interested in...
In Search Of Goodwill, Several Pharmas Commit To New Corporate ‘Statement Of Purpose’
The updated business principles may give pharma companies leverage, or at least talking points, as they continue to engage with the Trump administration on policies like the International Pricing Index and with US lawmakers on drug pricing legislation. J&J's Gorsky heads governing committee of multi-industry business group that revised its principles.
In Search Of Goodwill, Several Pharmas Commit To New Corporate ‘Statement Of Purpose’
The updated business principles may give pharma companies leverage, or at least talking points, as they continue to engage with the Trump administration on policies like the International Pricing Index and with US lawmakers on drug pricing legislation. J&J's Gorsky heads governing committee of multi-industry business group that revised its principles.
Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results
Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.